In Wednesday’s session, Shockwave Medical Inc. (NASDAQ:SWAV) marked $231.00 per share, up from $226.69 in the previous session. While Shockwave Medical Inc. has overperformed by 1.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWAV rose by 8.45%, with highs and lows ranging from $320.54 to $113.36, whereas the simple moving average fell by -0.44% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
On March 15, 2023, Needham started tracking Shockwave Medical Inc. (NASDAQ: SWAV) recommending Buy. A report published by Deutsche Bank on December 16, 2022, Initiated its previous ‘Buy’ rating for SWAV. Wells Fargo also Downgraded SWAV shares as ‘Equal Weight’, setting a target price of $235 on the company’s shares in a report dated December 12, 2022. Wolfe Research initiated its ‘Outperform’ rating for SWAV, as published in its report on April 06, 2022. BofA Securities’s report from March 02, 2022 suggests a price prediction of $200 for SWAV shares, giving the stock a ‘Buy’ rating. Wells Fargo also rated the stock as ‘Overweight’.
Analysis of Shockwave Medical Inc. (SWAV)
Further, the quarter-over-quarter increase in sales is 71.00%, showing a positive trend in the upcoming months.
Shockwave Medical Inc.’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 60.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 6.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and SWAV has an average volume of 474.53K. On a monthly basis, the volatility of the stock is set at 4.33%, whereas on a weekly basis, it is put at 3.71%, with a gain of 8.72% over the past seven days. Furthermore, long-term investors anticipate a median target price of $240.89, showing growth from the present price of $231.00, which can serve as yet another indication of whether SWAV is worth investing in or should be passed over.
How Do You Analyze Shockwave Medical Inc. Shares?
Medical Devices giant Shockwave Medical Inc. (SWAV) is based in the USA and is one of the largest companies in the market. When comparing Shockwave Medical Inc. shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 40.63, there is a growth in quarterly earnings of 910.60%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.90%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 92.60% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in SWAV shares?
The recent increase in stakes in SWAV appears to be a result of several institutional investors and hedge funds increasing their positions. BlackRock Fund Advisors’s position in SWAV has increased by 4.13% in the first quarter. The company now owns 3,938,859 shares of the stock, with a value of $749.33 million, following the purchase of 156,391 additional shares during the last quarter. The Vanguard Group, Inc. made another increased to its shares in SWAV during the first quarter, upping its stake by 4.70%. During the last quarter, the company dropped down 161,572 additional shares for a total stake of worth $684.62 million, bringing number of shares owned by the company to 3,598,702.
During the first quarter, Fidelity Management & Research Co subtracted a -63,987 position in SWAV. SSgA Funds Management, Inc. purchased an additional 14177.0 shares in the last quarter, increasing its holdings by 1.23%, now holding 1.17 million shares worth $222.86 million. At the end of the first quarter, T. Rowe Price Associates, Inc. decreased its SWAV holdings by -43.66% and now holds 1.01 million SWAV shares valued at $192.6 million with the lessened -0.78 million shares during the period. SWAV shares are owned by institutional investors to the tune of 92.60% at present.
